S&P 500   3,443.12 (+0.47%)
DOW   28,308.79 (+0.40%)
QQQ   284.41 (+0.21%)
AAPL   117.51 (+1.32%)
MSFT   214.65 (+0.20%)
FB   267.56 (+2.36%)
GOOGL   1,551.08 (+1.38%)
AMZN   3,217.01 (+0.31%)
TSLA   421.94 (-2.06%)
NVDA   545.82 (+1.09%)
BABA   309.81 (+1.48%)
CGC   18.88 (-4.69%)
GE   7.34 (+0.69%)
MU   53.53 (+1.71%)
AMD   81.56 (-0.54%)
T   26.76 (-0.45%)
F   7.74 (+1.98%)
ACB   4.56 (-3.18%)
GILD   60.55 (-0.03%)
NFLX   525.42 (-1.00%)
BA   167.24 (+0.08%)
BAC   24.14 (+1.77%)
DIS   124.95 (+0.58%)
S&P 500   3,443.12 (+0.47%)
DOW   28,308.79 (+0.40%)
QQQ   284.41 (+0.21%)
AAPL   117.51 (+1.32%)
MSFT   214.65 (+0.20%)
FB   267.56 (+2.36%)
GOOGL   1,551.08 (+1.38%)
AMZN   3,217.01 (+0.31%)
TSLA   421.94 (-2.06%)
NVDA   545.82 (+1.09%)
BABA   309.81 (+1.48%)
CGC   18.88 (-4.69%)
GE   7.34 (+0.69%)
MU   53.53 (+1.71%)
AMD   81.56 (-0.54%)
T   26.76 (-0.45%)
F   7.74 (+1.98%)
ACB   4.56 (-3.18%)
GILD   60.55 (-0.03%)
NFLX   525.42 (-1.00%)
BA   167.24 (+0.08%)
BAC   24.14 (+1.77%)
DIS   124.95 (+0.58%)
S&P 500   3,443.12 (+0.47%)
DOW   28,308.79 (+0.40%)
QQQ   284.41 (+0.21%)
AAPL   117.51 (+1.32%)
MSFT   214.65 (+0.20%)
FB   267.56 (+2.36%)
GOOGL   1,551.08 (+1.38%)
AMZN   3,217.01 (+0.31%)
TSLA   421.94 (-2.06%)
NVDA   545.82 (+1.09%)
BABA   309.81 (+1.48%)
CGC   18.88 (-4.69%)
GE   7.34 (+0.69%)
MU   53.53 (+1.71%)
AMD   81.56 (-0.54%)
T   26.76 (-0.45%)
F   7.74 (+1.98%)
ACB   4.56 (-3.18%)
GILD   60.55 (-0.03%)
NFLX   525.42 (-1.00%)
BA   167.24 (+0.08%)
BAC   24.14 (+1.77%)
DIS   124.95 (+0.58%)
S&P 500   3,443.12 (+0.47%)
DOW   28,308.79 (+0.40%)
QQQ   284.41 (+0.21%)
AAPL   117.51 (+1.32%)
MSFT   214.65 (+0.20%)
FB   267.56 (+2.36%)
GOOGL   1,551.08 (+1.38%)
AMZN   3,217.01 (+0.31%)
TSLA   421.94 (-2.06%)
NVDA   545.82 (+1.09%)
BABA   309.81 (+1.48%)
CGC   18.88 (-4.69%)
GE   7.34 (+0.69%)
MU   53.53 (+1.71%)
AMD   81.56 (-0.54%)
T   26.76 (-0.45%)
F   7.74 (+1.98%)
ACB   4.56 (-3.18%)
GILD   60.55 (-0.03%)
NFLX   525.42 (-1.00%)
BA   167.24 (+0.08%)
BAC   24.14 (+1.77%)
DIS   124.95 (+0.58%)
Log in
OTCMKTS:STDAF

STADA Arzneimittel Aktiengesellschaft Stock Forecast, Price & News

$115.00
0.00 (0.00 %)
(As of 10/20/2020 12:00 AM ET)
Add
Compare
Today's Range
$115.00
Now: $115.00
$115.00
50-Day Range
$110.00
MA: $112.60
$115.00
52-Week Range
$75.15
Now: $115.00
$115.00
VolumeN/A
Average Volume178 shs
Market Capitalization$7.17 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.64
STADA Arzneimittel Aktiengesellschaft engages in the health care and pharmaceuticals business worldwide. The company operates in two segments, Generics and Branded Products. The Generics segment provides various generic active ingredients, including Tilidin Naloxon for pain; Atorvastatin for elevated cholesterol levels; Epoetin zeta for anemia; and Omeprazol and Pantoprazol for gastric ulcer/reflux. The Branded Products segment offers Bortezomib STADA for cancer; APO-Go for Parkinson's disease; Grippostad for cold; Zoflora for disinfections; and Snup for head cold. The company serves doctors, pharmacists, patients, health insurance organizations, buying groups, pharmacy chains, and wholesalers or mail-order companies. It has strategic partnership with XBrane Biopharma for the development of biosimilars; and Alvotech ehf for the marketing of biosimilars. The company was founded in 1895 and is headquartered in Bad Vilbel, Germany. STADA Arzneimittel Aktiengesellschaft is a subsidiary of Nidda Healthcare GmbH.
Read More
STADA Arzneimittel Aktiengesellschaft logo

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.40 out of 5 stars

Industry, Sector and Symbol

Industry Medicinals & botanicals
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:STDAF
Previous SymbolNASDAQ:STDAF
CUSIPN/A
CIKN/A
Phone49-6101-6030
Employees12,339

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$2.75 billion
Cash Flow$8.57 per share
Book Value$22.32 per share

Profitability

Miscellaneous

Market Cap$7.17 billion
Next Earnings DateN/A
OptionableNot Optionable
$115.00
0.00 (0.00 %)
(As of 10/20/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive STDAF News and Ratings via Email

Sign-up to receive the latest news and ratings for STDAF and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











STADA Arzneimittel Aktiengesellschaft (OTCMKTS:STDAF) Frequently Asked Questions

How has STADA Arzneimittel Aktiengesellschaft's stock price been impacted by COVID-19 (Coronavirus)?

STADA Arzneimittel Aktiengesellschaft's stock was trading at $88.92 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, STDAF stock has increased by 29.3% and is now trading at $115.00.
View which stocks have been most impacted by COVID-19
.

Who are some of STADA Arzneimittel Aktiengesellschaft's key competitors?

Who are STADA Arzneimittel Aktiengesellschaft's key executives?

STADA Arzneimittel Aktiengesellschaft's management team includes the following people:
  • Mr. Peter Goldschmidt, Chairman of the Exec. Board & CEO (Age 56)
  • Mr. Miguel Pagan Fernandez, CTO & Member of Exec. Board (Age 55)
  • Dr. Wolfgang Ollig, Group Chief Financial Officer & Member of Exec. Board
  • Dr. Christoph Dengler, Exec. VP of Global Legal
  • Mr. Frank Staud, Exec. VP of Global Communications & Branding

What is STADA Arzneimittel Aktiengesellschaft's stock symbol?

STADA Arzneimittel Aktiengesellschaft trades on the OTCMKTS under the ticker symbol "STDAF."

How do I buy shares of STADA Arzneimittel Aktiengesellschaft?

Shares of STDAF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is STADA Arzneimittel Aktiengesellschaft's stock price today?

One share of STDAF stock can currently be purchased for approximately $115.00.

How big of a company is STADA Arzneimittel Aktiengesellschaft?

STADA Arzneimittel Aktiengesellschaft has a market capitalization of $7.17 billion and generates $2.75 billion in revenue each year. STADA Arzneimittel Aktiengesellschaft employs 12,339 workers across the globe.

What is STADA Arzneimittel Aktiengesellschaft's official website?

The official website for STADA Arzneimittel Aktiengesellschaft is www.stada.com.

How can I contact STADA Arzneimittel Aktiengesellschaft?

STADA Arzneimittel Aktiengesellschaft's mailing address is Stadastrasse 2-18, Bad Vilbel 2M, 61118. The company can be reached via phone at 49-6101-6030 or via email at [email protected]

This page was last updated on 10/20/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.